Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma

Lan B. Hoang-Minh; Florian A. Siebzehnrubl; Changlin Yang; Silveli Suzuki-Hatano; Kyle Dajac; Tyler Loche; Nicholas Andrews; Michael Schmoll Massari; Jaimin Patel; Krisha Amin; Alvin Vuong; Ana Jimenez-Pascual; Paul Kubilis; Timothy J. Garrett; Craig Moneypenny; Christina A. Pacak; Jianping Huang; Elias J. Sayour; Duane A. Mitchell; Matthew R. Sarkisian; Brent A. Reynolds; Loic P. Deleyrolle

doi:10.15252/embj.201798772

Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma

Lan B. Hoang-Minh, Florian A. Siebzehnrubl, Changlin Yang, Silveli Suzuki-Hatano, Kyle Dajac, Tyler Loche, Nicholas Andrews, Michael Schmoll Massari, Jaimin Patel, Krisha Amin, Alvin Vuong, Ana Jimenez-Pascual, Paul Kubilis, Timothy J. Garrett, Craig Moneypenny, Christina A. Pacak, Jianping Huang, Elias J. Sayour, Duane A. Mitchell, Matthew R. SarkisianBrent A. Reynolds, Loic P. Deleyrolle

Research output: Contribution to journal › Article › peer-review

102 Scopus citations

Abstract

Metabolic reprogramming has been described in rapidly growing tumors, which are thought to mostly contain fast-cycling cells (FCCs) that have impaired mitochondrial function and rely on aerobic glycolysis. Here, we characterize the metabolic landscape of glioblastoma (GBM) and explore metabolic specificities as targetable vulnerabilities. Our studies highlight the metabolic heterogeneity in GBM, in which FCCs harness aerobic glycolysis, and slow-cycling cells (SCCs) preferentially utilize mitochondrial oxidative phosphorylation for their functions. SCCs display enhanced invasion and chemoresistance, suggesting their important role in tumor recurrence. SCCs also demonstrate increased lipid contents that are specifically metabolized under glucose-deprived conditions. Fatty acid transport in SCCs is targetable by pharmacological inhibition or genomic deletion of FABP7, both of which sensitize SCCs to metabolic stress. Furthermore, FABP7 inhibition, whether alone or in combination with glycolysis inhibition, leads to overall increased survival. Our studies reveal the existence of GBM cell subpopulations with distinct metabolic requirements and suggest that FABP7 is central to lipid metabolism in SCCs and that targeting FABP7-related metabolic pathways is a viable therapeutic strategy.

Original language	English (US)
Article number	e98772
Journal	EMBO Journal
Volume	37
Issue number	23
DOIs	https://doi.org/10.15252/embj.201798772
State	Published - Dec 3 2018
Externally published	Yes

Bibliographical note

Funding Information:
Financial support was provided by American Brain Tumor Association Basic Research Fellowship Grant (L.H.M.), Tenovus Cancer Care TIG2015/L19 and the Cancer Research UK Cardiff Centre (F.A.S.), Preston A. Wells, Jr. Endowment 00107592 (J.H.), 1K08CA199224-01A1 (E.J.S.), American Cancer Society Research Scholar Grant RSG-13-031-01-DDC (M.R.S.), Preston A. Wells, Jr. Brain Tumor Research Fund (D.A.M.), NINDS R24 NS086554-01 (B.A.R.), American Cancer Society Chris DiMarco Institutional Research Grant, Accelerate Brain Cancer Cure, American Brain Tumor Association Research Grant DG1800014, and Preston A. Wells, Jr. Brain Tumor Research Fund (L.P.D.). This study was supported by the Robert P. Apkarian Integrated Electron Microscopy Core (RPAIEMC), which is subsidized by the Emory College of Arts and Sciences and the Emory University School of Medicine and is one of the Emory Integrated Core Facilities. The authors would like to thank the University of Florida Interdisciplinary Center for Biotechnology Research Cytometry Core (N. Benson and A. Doty), the Cell & Tissue Analysis Core (D. Smith, NIH Grant # 1S10OD020026), M. Dajac and M. Andrews for technical assistance, the Florida Center for Brain Tumor Research (B. Frentzen, R. McTiernan, and J. Pittman) for access to brain tumor samples, and B. Tugertimur for his assistance in setting up the MTT assays.

Funding Information:
LBH-M, FAS, MRS, CAP, BAR, and LPD conceived and designed the research studies; LBH-M, FAS, CY, KD, TL, NA, MSM, JP, KA, AV, AJ-P, SS-H, CM, and LPD collected and/or assembled the data; LBH-M, FAS, CY, JH, EJS, TJG, DAM, SS-H, CAP, PK, MRS, BAR, and LPD analyzed and interpreted the data; LBH-M, FAS, EJS, and, LPD wrote the manuscript. FAS, DAM, MRS, BAR, and LPD provided financial support. All authors gave final approval of the manuscript.

Publisher Copyright:
© 2018 The Authors

Keywords

brain cancer
cancer stem cells
glioblastoma
metabolism
slow-cycling cells

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.15252/embj.201798772

OpenUrl availability

Full text

Cite this

Hoang-Minh, L. B., Siebzehnrubl, F. A., Yang, C., Suzuki-Hatano, S., Dajac, K., Loche, T., Andrews, N., Schmoll Massari, M., Patel, J., Amin, K., Vuong, A., Jimenez-Pascual, A., Kubilis, P., Garrett, T. J., Moneypenny, C., Pacak, C. A., Huang, J., Sayour, E. J., Mitchell, D. A., ... Deleyrolle, L. P. (2018). Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma. EMBO Journal, 37(23), Article e98772. https://doi.org/10.15252/embj.201798772

Hoang-Minh, LB, Siebzehnrubl, FA, Yang, C, Suzuki-Hatano, S, Dajac, K, Loche, T, Andrews, N, Schmoll Massari, M, Patel, J, Amin, K, Vuong, A, Jimenez-Pascual, A, Kubilis, P, Garrett, TJ, Moneypenny, C, Pacak, CA, Huang, J, Sayour, EJ, Mitchell, DA, Sarkisian, MR, Reynolds, BA & Deleyrolle, LP 2018, 'Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma', EMBO Journal, vol. 37, no. 23, e98772. https://doi.org/10.15252/embj.201798772

@article{2cbd07b5ef934473844dc639a51c91b6,

title = "Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma",

abstract = "Metabolic reprogramming has been described in rapidly growing tumors, which are thought to mostly contain fast-cycling cells (FCCs) that have impaired mitochondrial function and rely on aerobic glycolysis. Here, we characterize the metabolic landscape of glioblastoma (GBM) and explore metabolic specificities as targetable vulnerabilities. Our studies highlight the metabolic heterogeneity in GBM, in which FCCs harness aerobic glycolysis, and slow-cycling cells (SCCs) preferentially utilize mitochondrial oxidative phosphorylation for their functions. SCCs display enhanced invasion and chemoresistance, suggesting their important role in tumor recurrence. SCCs also demonstrate increased lipid contents that are specifically metabolized under glucose-deprived conditions. Fatty acid transport in SCCs is targetable by pharmacological inhibition or genomic deletion of FABP7, both of which sensitize SCCs to metabolic stress. Furthermore, FABP7 inhibition, whether alone or in combination with glycolysis inhibition, leads to overall increased survival. Our studies reveal the existence of GBM cell subpopulations with distinct metabolic requirements and suggest that FABP7 is central to lipid metabolism in SCCs and that targeting FABP7-related metabolic pathways is a viable therapeutic strategy.",

keywords = "brain cancer, cancer stem cells, glioblastoma, metabolism, slow-cycling cells",

author = "Hoang-Minh, {Lan B.} and Siebzehnrubl, {Florian A.} and Changlin Yang and Silveli Suzuki-Hatano and Kyle Dajac and Tyler Loche and Nicholas Andrews and {Schmoll Massari}, Michael and Jaimin Patel and Krisha Amin and Alvin Vuong and Ana Jimenez-Pascual and Paul Kubilis and Garrett, {Timothy J.} and Craig Moneypenny and Pacak, {Christina A.} and Jianping Huang and Sayour, {Elias J.} and Mitchell, {Duane A.} and Sarkisian, {Matthew R.} and Reynolds, {Brent A.} and Deleyrolle, {Loic P.}",

note = "Funding Information: Financial support was provided by American Brain Tumor Association Basic Research Fellowship Grant (L.H.M.), Tenovus Cancer Care TIG2015/L19 and the Cancer Research UK Cardiff Centre (F.A.S.), Preston A. Wells, Jr. Endowment 00107592 (J.H.), 1K08CA199224-01A1 (E.J.S.), American Cancer Society Research Scholar Grant RSG-13-031-01-DDC (M.R.S.), Preston A. Wells, Jr. Brain Tumor Research Fund (D.A.M.), NINDS R24 NS086554-01 (B.A.R.), American Cancer Society Chris DiMarco Institutional Research Grant, Accelerate Brain Cancer Cure, American Brain Tumor Association Research Grant DG1800014, and Preston A. Wells, Jr. Brain Tumor Research Fund (L.P.D.). This study was supported by the Robert P. Apkarian Integrated Electron Microscopy Core (RPAIEMC), which is subsidized by the Emory College of Arts and Sciences and the Emory University School of Medicine and is one of the Emory Integrated Core Facilities. The authors would like to thank the University of Florida Interdisciplinary Center for Biotechnology Research Cytometry Core (N. Benson and A. Doty), the Cell & Tissue Analysis Core (D. Smith, NIH Grant # 1S10OD020026), M. Dajac and M. Andrews for technical assistance, the Florida Center for Brain Tumor Research (B. Frentzen, R. McTiernan, and J. Pittman) for access to brain tumor samples, and B. Tugertimur for his assistance in setting up the MTT assays. Funding Information: LBH-M, FAS, MRS, CAP, BAR, and LPD conceived and designed the research studies; LBH-M, FAS, CY, KD, TL, NA, MSM, JP, KA, AV, AJ-P, SS-H, CM, and LPD collected and/or assembled the data; LBH-M, FAS, CY, JH, EJS, TJG, DAM, SS-H, CAP, PK, MRS, BAR, and LPD analyzed and interpreted the data; LBH-M, FAS, EJS, and, LPD wrote the manuscript. FAS, DAM, MRS, BAR, and LPD provided financial support. All authors gave final approval of the manuscript. Publisher Copyright: {\textcopyright} 2018 The Authors",

year = "2018",

month = dec,

day = "3",

doi = "10.15252/embj.201798772",

language = "English (US)",

volume = "37",

journal = "EMBO Journal",

issn = "0261-4189",

publisher = "Nature Publishing Group",

number = "23",

}

TY - JOUR

T1 - Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma

AU - Hoang-Minh, Lan B.

AU - Siebzehnrubl, Florian A.

AU - Yang, Changlin

AU - Suzuki-Hatano, Silveli

AU - Dajac, Kyle

AU - Loche, Tyler

AU - Andrews, Nicholas

AU - Schmoll Massari, Michael

AU - Patel, Jaimin

AU - Amin, Krisha

AU - Vuong, Alvin

AU - Jimenez-Pascual, Ana

AU - Kubilis, Paul

AU - Garrett, Timothy J.

AU - Moneypenny, Craig

AU - Pacak, Christina A.

AU - Huang, Jianping

AU - Sayour, Elias J.

AU - Mitchell, Duane A.

AU - Sarkisian, Matthew R.

AU - Reynolds, Brent A.

AU - Deleyrolle, Loic P.

N1 - Funding Information: Financial support was provided by American Brain Tumor Association Basic Research Fellowship Grant (L.H.M.), Tenovus Cancer Care TIG2015/L19 and the Cancer Research UK Cardiff Centre (F.A.S.), Preston A. Wells, Jr. Endowment 00107592 (J.H.), 1K08CA199224-01A1 (E.J.S.), American Cancer Society Research Scholar Grant RSG-13-031-01-DDC (M.R.S.), Preston A. Wells, Jr. Brain Tumor Research Fund (D.A.M.), NINDS R24 NS086554-01 (B.A.R.), American Cancer Society Chris DiMarco Institutional Research Grant, Accelerate Brain Cancer Cure, American Brain Tumor Association Research Grant DG1800014, and Preston A. Wells, Jr. Brain Tumor Research Fund (L.P.D.). This study was supported by the Robert P. Apkarian Integrated Electron Microscopy Core (RPAIEMC), which is subsidized by the Emory College of Arts and Sciences and the Emory University School of Medicine and is one of the Emory Integrated Core Facilities. The authors would like to thank the University of Florida Interdisciplinary Center for Biotechnology Research Cytometry Core (N. Benson and A. Doty), the Cell & Tissue Analysis Core (D. Smith, NIH Grant # 1S10OD020026), M. Dajac and M. Andrews for technical assistance, the Florida Center for Brain Tumor Research (B. Frentzen, R. McTiernan, and J. Pittman) for access to brain tumor samples, and B. Tugertimur for his assistance in setting up the MTT assays. Funding Information: LBH-M, FAS, MRS, CAP, BAR, and LPD conceived and designed the research studies; LBH-M, FAS, CY, KD, TL, NA, MSM, JP, KA, AV, AJ-P, SS-H, CM, and LPD collected and/or assembled the data; LBH-M, FAS, CY, JH, EJS, TJG, DAM, SS-H, CAP, PK, MRS, BAR, and LPD analyzed and interpreted the data; LBH-M, FAS, EJS, and, LPD wrote the manuscript. FAS, DAM, MRS, BAR, and LPD provided financial support. All authors gave final approval of the manuscript. Publisher Copyright: © 2018 The Authors

PY - 2018/12/3

Y1 - 2018/12/3

N2 - Metabolic reprogramming has been described in rapidly growing tumors, which are thought to mostly contain fast-cycling cells (FCCs) that have impaired mitochondrial function and rely on aerobic glycolysis. Here, we characterize the metabolic landscape of glioblastoma (GBM) and explore metabolic specificities as targetable vulnerabilities. Our studies highlight the metabolic heterogeneity in GBM, in which FCCs harness aerobic glycolysis, and slow-cycling cells (SCCs) preferentially utilize mitochondrial oxidative phosphorylation for their functions. SCCs display enhanced invasion and chemoresistance, suggesting their important role in tumor recurrence. SCCs also demonstrate increased lipid contents that are specifically metabolized under glucose-deprived conditions. Fatty acid transport in SCCs is targetable by pharmacological inhibition or genomic deletion of FABP7, both of which sensitize SCCs to metabolic stress. Furthermore, FABP7 inhibition, whether alone or in combination with glycolysis inhibition, leads to overall increased survival. Our studies reveal the existence of GBM cell subpopulations with distinct metabolic requirements and suggest that FABP7 is central to lipid metabolism in SCCs and that targeting FABP7-related metabolic pathways is a viable therapeutic strategy.

AB - Metabolic reprogramming has been described in rapidly growing tumors, which are thought to mostly contain fast-cycling cells (FCCs) that have impaired mitochondrial function and rely on aerobic glycolysis. Here, we characterize the metabolic landscape of glioblastoma (GBM) and explore metabolic specificities as targetable vulnerabilities. Our studies highlight the metabolic heterogeneity in GBM, in which FCCs harness aerobic glycolysis, and slow-cycling cells (SCCs) preferentially utilize mitochondrial oxidative phosphorylation for their functions. SCCs display enhanced invasion and chemoresistance, suggesting their important role in tumor recurrence. SCCs also demonstrate increased lipid contents that are specifically metabolized under glucose-deprived conditions. Fatty acid transport in SCCs is targetable by pharmacological inhibition or genomic deletion of FABP7, both of which sensitize SCCs to metabolic stress. Furthermore, FABP7 inhibition, whether alone or in combination with glycolysis inhibition, leads to overall increased survival. Our studies reveal the existence of GBM cell subpopulations with distinct metabolic requirements and suggest that FABP7 is central to lipid metabolism in SCCs and that targeting FABP7-related metabolic pathways is a viable therapeutic strategy.

KW - brain cancer

KW - cancer stem cells

KW - glioblastoma

KW - metabolism

KW - slow-cycling cells

UR - http://www.scopus.com/inward/record.url?scp=85055047225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055047225&partnerID=8YFLogxK

U2 - 10.15252/embj.201798772

DO - 10.15252/embj.201798772

M3 - Article

C2 - 30322894

AN - SCOPUS:85055047225

SN - 0261-4189

VL - 37

JO - EMBO Journal

JF - EMBO Journal

IS - 23

M1 - e98772

ER -

Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this